| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14813ba46a31b6b6790569d56f5e388d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-642
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-521 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2017-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_737bc96417e70f52a7ee162b78878379 |
| publicationDate |
2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018094309-A2 |
| titleOfInvention |
Fractal combination therapy |
| abstract |
Contemplated compositions and methods generate a durable immune synapse and so lead to activated T-cells and memory T-cell formation by use of selected co-stimulatory receptors and their ligands in conjunction with selected neoepitopes. Moreover, immune competent cells are attracted into a tumor microenvironment after activation of the T-cells using hybrid or chimeric binding proteins that comprise a chemokine portion and that target components of necrotic cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3475434-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779637-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3615675-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11154597-B2 |
| priorityDate |
2016-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |